Tag: interferon gamma-1b

Horizon hit by Actimimmune fail in Friedrich’s ataxia

by Selina McKee | Dec 9, 2016 | News | 0

Horizon Pharma shares dropped 20 percent after the company pulled the plug a late-stage trial testing Actimmune as a potential therapy Friedreich’s ataxia.

Horizon picks up interferon gamma-1b rights from Boehringer

by Selina McKee | May 20, 2016 | News | 0

Dublin-Ireland based biopharma Horizon Pharma has bagged rights to Boehringer Ingelheim’s interferon gamma-1b in an around 30 countries primarily in Europe and the Middle East for 25 million euros.